Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > BMS buys stock in TCR-based cell therapies & bispecifics co.

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 27, 2023 3:33pm

159 Views

Post# 35560259

RE:BMS buys stock in TCR-based cell therapies & bispecifics co.

July 27, 203 - BMS looks to new product portfolio as revenues slide due to Revlimid losses

Bristol Myers Squibb cited lower Revlimid sales as a driver of its falling revenue in the US in the second quarter of 2023, and like other Big Pharma companies is looking to recover from a looming patent cliff that has begun to take affect in 2023. Big Pharma will be also looking to M&A deals to fill their threatened product portfolios, that are losing their product market exclusivities.

https://endpts.com/revlimid-losses-lead-bristol-myers-squibb-to-lower-full-year-guidance/

<< Previous

Bullboard Posts

Next >>

StockTalk | Cannabis Report: New CEO, new dispensaries, new strains